On June 11, 2025, Wandercraft, a pioneer in self-balancing robotic mobility, announced a $75 million Series D funding round. Investors include Renault Group, Bpifrance, Teampact Ventures, Quadrant Management, and other firms. This latest infusion brings the startup’s total funding to date to approximately $75 million, positioning the company for strategic growth across rehabilitation, consumer mobility, and industrial robotics.
Strategic funding and growth trajectory
Wandercraft’s Series D follows the €25 million loan from EIB in April 2024, aimed at personal exoskeleton development, and the $45 million Series C closed in early 2022. According to Dealroom, the company raised $45.38 million in that round. Series C helped fuel U.S. expansion, resulted in a ten‑fold revenue increase and enabled regulatory clearances for its flagship rehabilitation platform, Atalante X.
The fresh capital will support:
Commercial rollout of Eve, the world’s first self-balanced personal exoskeleton.
Scaling clinical use of Atalante X, now deployed in over 100 institutions.
Industrial deployment of Calvin‑40 and expansion of the Calvin humanoid line.
Clinical and rehabilitation advances
Atalante X: Expanding clinical footprint
Atalante X, Wandercraft’s rehabilitation exoskeleton, continues securing clinical traction. It recently gained its second FDA clearance (following stroke rehab) for spinal cord injury (T5–L5) in December 2023, enabling deployment in top-tier U.S. centers including Kessler Foundation and Vivantes Klinikum.
Key clinical results so far include:
- Deployment in over 100 hospitals worldwide
- Participation in more than 20 clinical studies
- Positive outcomes: improved walking speed, balance, muscle strength, and reduced spasticity
- Cumulative usage: ~2,500 users taking over 14 million step
Eve personal exoskeleton: Hands-free mobility
Eve is being positioned as a personal mobility breakthrough, designed for individuals with severe mobility loss. Wandercraft launched the first clinical trial of Eve, which supports hands-free walking in home and outdoor settings. Plans include U.S. market debut by 2026.
A new exoskeleton walking center has opened in New York’s Cure® innovation campus, offering pre-launch access and gauging real-world usability in preparation for its broader rollout. The trial evaluates endurance, ease of movement, and user integration in daily life.
]Industrial robotics: Entering the factory floor
Calvin‑40: Europe’s first humanoid robot for industry
Calvin‑40, a full-sized humanoid robot, has been co-developed with Renault Group, whose minority investment allows industrial scaling and commercialization. Designed to take on physically demanding tasks in factories, Calvin‑40 is slated for production deployment within 40 weeks at Renault plants.
Wandercraft utilized its advanced platform, rapid prototyping, and NVIDIA’s Jetson AI and Visual Language Model to accelerate development atop its existing AI core.
Strategic partnership with renault
Renault’s participation as both investor and first commercial customer signals a deep industrial alignment. According to CEO Matthieu Masselin:
“As both a minority investor and commercial customer, [Renault] have and will continue to provide valuable input. … We found very strong alignment on both the short and long term objectives.”
The collaboration is crafted to preserve Wandercraft’s autonomy over Calvin‑40’s roadmap, while leveraging Renault’s manufacturing scale. The agreement also paves the way for cost‑efficient mass production of Eve and future Calvin robots. Masselin emphasized Renault’s trust in Wandercraft’s reliability and platform advantage.
Technical and regulatory Insights
Emphasis on safety and reliability
During our email interview, Masselin described safety as the primary technical challenge. He explained:
“It’s about first building a device that has multiple protections for its users, from software like stopping when it senses a disturbance in the ground, to hardware like armrests or the jacket that keep the user safe.”
Both Eve and Calvin are built to automotive-level safety standards:
Eve is being designed to 5-star car crash-test safety levels.
Calvin’s safety protocols ensure usability regardless of operator or context.
Implementing these advanced protections has added development time but did not significantly delay project timelines.
Regulatory pathways and market entry
Eve’s U.S. launch will leverage existing Medicare reimbursement frameworks for personal exoskeletons, along with private insurer support. Masselin stated:
“Medicare has been reimbursing Personal Exoskeletons in the US for over a year now… We look forward to working with regulators, public, and private payors to bring Eve to market and ensure it is as accessible as possible.”
Pricing details for Calvin‑40 are being negotiated directly with industrial partners; however, according to Masselin, “the ROI case is compelling to everyone we are speaking with.”
Risk landscape and ethical considerations
Competition and technological pace
When asked about competitive threats, Masselin responded:
“We’re not worried about the competition. Our relentless focus is development speed, device quality, and ensuring we are building robots… that improve the lives of our customers.”
He cited Renault’s deep experience with robotics as validation of Wandercraft’s edge in reliability and platform leverage.
Worker safety and job displacement
Wandercraft’s focus remains on robots handling tasks that are dangerous or ergonomically risky:
“[We] focus… on those jobs which are strenuous, dangerous, and leading to possibly musculoskeletal injury.”
The company argues that this automation wave continues past trends from the 1970s and 1980s, targeting residual physically demanding tasks. Future ambitions include humanoid caregivers to support persons with reduced autonomy.
Broader industry context
The lower-limb exoskeleton market is expected to grow significantly from 2025 to 2030, driven by aging populations and rising demand for mobility assistance. Meanwhile, Wandercraft’s Atalante X is among a select group with solid FDA and CE approvals.
Compared with competitors like Ekso Bionics and ReWalk Robotics, Wandercraft claims a true bipedal gait replicating human walking, sans crutches. This reduces strain and enables hands-free operation—factors patients and rehab centers value highly.
Awards, recognition & market visibility
- Olympic & Paralympic 2024 Torch Relay: Wandercraft featured Eve during the relay.
- CES 2025 & NVIDIA GTC: Showcased AI-powered exoskeleton capabilities built on NVIDIA’s Jetson platform.
- SXSW 2025 Innovation Award: Honored in AI for its transformative exoskeleton developments.
These highlights underscore the company’s growing reputation at the intersection of AI and physical robotics.
Challenges ahead
Wandercraft faces several headwinds:
Scaling manufacturing of Eve and Calvin, even with Renault’s support.
Regulatory timelines, particularly for widespread public and home use.
Reimbursement complexity, managing Medicare, private payors, and price negotiations.
Market adoption risks, especially in conservative clinical or industrial settings.
However, strong clinical data, existing FDA approval, and early partnerships suggest the company is in a solid position to navigate these challenges.
Are they on the cusp of market expansion
Wandercraft’s Series D financing marks a major milestone in its evolution from clinical exoskeleton pioneer to diversified robotics company spanning personal mobility and industrial automation. With Eve targeting consumer markets by 2026 and Calvin‑40 poised for early factory deployment, Wandercraft has multiple commercialization tracks.
The collaboration with Renault combines industrial-scale manufacturing with AI-enabled robotics, while clinical momentum—driven by Atalante X’s approval and trial data—serves as a strong foundation. The company is similarly addressing regulatory and reimbursement barriers proactively.
Challenges remain, especially around scaling and pricing for broad accessibility. But Wandercraft’s articulated strategy—technical rigor in safety, strong partnerships, visible awards, and real-world usage—places it among the most promising players in the fast-growing exoskeleton and humanoid robotics sectors.
